Recent Updates
Recently added Catalysts

PepGen Inc.

PEPG
Richly ValuedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$2.58
▲ +0.2 · +8.4%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PEPG financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.3152W HIGH $7.80
Volume
171.12 K
Value Traded
4.42 M
Short % Float
6.26%
+13.16%Week
-18.1%1 Month
+10.26%3 Month
+57.32%6 Month
-90.32%5 Year
-90.32%All Time

Cash Data

Unlock PEPG cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
179.04 M
EPS (TTM)
-1.04
P/E Ratio
-
Ent. Value
61.11 M
Total Shares
69.24 M
Float Shares
61.80 M
Insiders
10.77%
Institutions
71.85%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout
PGN-EDODM1
Myotonic Dystrophy Type 1
Fast TrackOrphan
Phase 1RNA-Based TherapiesRare Diseases
Unlock every PEPG catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PEPG Catalyst Timeline

Dated clinical, regulatory and corporate events for PepGen Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for PepGen Inc.

274Total events
10Upcoming
54Tier-1 (high impact)
2021 to 2027Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
PGN-EDODM1
T2Quarterly Update
Subscribe to view catalyst details
PGN-EDODM1

Event history 50

▲DSMB ReviewPGN-EDODM1Trial
DSMB recommended advancing to highest dose cohort (12.5 mg/kg) in FREEDOM2-DM1
myotonic dystrophy type 1 (DM1)source ↗
▲Enrollment MilestonePGN-EDODM1Trial
OLE enrollment reached 16 participants; 6 of 8 from 5 mg/kg cohort elected to enroll
myotonic dystrophy type 1 (DM1)source ↗
▲EU Orphan DesignationPGN-EDODM1Ex-US Regulatory
EMA granted Orphan Designation for PGN-EDODM1
myotonic dystrophy type 1 (DM1)source ↗
▲Topline ReadoutPGN-EDODM1Clinical Data
Topline results from 5 mg/kg MAD cohort of FREEDOM2
Myotonic Dystrophy Type 1 (DM1)source ↗
▲Enrollment CompletePGN-EDODM1Trial
FREEDOM2 10 mg/kg cohort fully enrolled
Myotonic Dystrophy Type 1 (DM1)source ↗
▼Partial Clinical HoldPGN-EDODM1IND
FDA placed partial clinical hold on FREEDOM2
Myotonic Dystrophy Type 1 (DM1)source ↗
▲Other Regulator MilestonePGN-EDODM1Ex-US Regulatory
Regulatory clearance to initiate FREEDOM2 in South Korea, Australia, New Zealand
Myotonic Dystrophy Type 1 (DM1)source ↗
▲Enrollment UpdatePGN-EDODM1Trial
OLE enrollment reached 16 participants
myotonic dystrophy type 1 (DM1)source ↗
●Quarterly UpdateCorporate
PepGen reported second quarter 2026 financial results
source ↗
▲Runway Guidance UpdateCorporate
Cash sufficient to fund operations into 2H 2027
source ↗
Unlock the full PEPG catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PEPG actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-09-30PGN-EDO51 Phase 2 data readout Phase 2
Unlock 1 more PEPG historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D33 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 61%
Micro Cap
(rank 402 of 658)
Percentile Rank
PepGen Inc. faces pipeline headwinds (33/100), with $12M risk-adjusted pipeline value, led by PGN-EDODM1 in Myotonic Dystrophy 1 (Phase 2).
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
PGN-EDODM1 Small moleculeNCT06667453Myotonic Dystrophy 1Phase 2 RECRUITING 72Mar 1, 2027
Unlock the PEPG pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every PEPG program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
PGN-EDODM1
Fast TrackOrphan
Myotonic Dystrophy Type 1 (DM1)Phase 12026-03-05splicing correction: 5 mg/kg 12.3%, 10 mg/kg 29.1%, 15 mg/kg 53.7%; safety: PGN-EDODM1 was generally well-tolerated across all doses; treatment-emergent adverse events (TEAEs) were mild to moderate, transient, and required no intervention.Read MorePepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate HighlightsRead More
Scroll for more · summaries link to the source press release
Unlock every PEPG trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PEPG insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Kasraian KasraOfficer (Chief Technical Officer)Sell -1,233 50,074 held$1.41 05/21/2026
Unlock the full PEPG insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in PEPG

Fund % of Portfolio Current MV Shares Owned Activity
RA CAPITAL MANAGEMENT, L.P. 0.3 % (-25 %) 36.12 M 20.06 M
Unlock every fund holding PEPG
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PEPG
Shares held by hedge funds each quarter, and who bought or sold.

PEPG Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-10-16
Unlock PEPG option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PEPG option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PEPG options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PEPG ranks across every disease it competes in

Competitive Position is a premium feature
See how PEPG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PEPG News

PEPG
Aug 6, 2026
PEPGGeneral
▲ +21.7%on this news· ran to +46% by day 3

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen has released its financial results for the second quarter of 2026, alongside recent corporate highlights. The report provides insights into the company's performance and strategic developments during this period. Further details on financial metrics and corporate activities were not disclosed in the provided text.

Read more →
PEPG
Aug 6, 2026
PEPGPhases
▲ +21.7%on this news· ran to +46% by day 3shared move

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen has announced the advancement of its drug PGN-EDODM1 into the highest dose cohort of the Phase 2 FREEDOM2-DM1 study. This decision follows a favorable review by the Data Safety Monitoring Board (DSMB), indicating confidence in the drug's safety and potential efficacy.

Read more →
PEPG
May 21, 2026
PEPGConferences/Events
▲ +6.9%on this news

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

PepGen has announced its participation in the 15th International Myotonic Dystrophy Consortium. The company will present clinical data related to its PGN-EDODM1 program. Further details regarding the findings or implications of the data were not provided in the announcement.

Read more →
PEPG
May 21, 2026
PEPGPhases
▲ +6.9%on this news

Company Presentation May 2026 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may

PepGen presented forward-looking statements regarding their investigational therapy, PGN-EDODM1, highlighting its potential in treating Myotonic Dystrophy Type 1 (DM1). The presentation stressed the advantages of the EDO platform in facilitating oligonucleotide delivery to nuclei. Positive results from clinical trials indicate an emerging safety profile, while ongoing regulatory discussions play a critical role in the therapy's future. However, potential risks include slow enrollment in clinical trials and the impact of regulatory decisions on development timelines.

Read more →
PEPG
May 12, 2026
PEPGGeneral

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen has reported its financial results for the first quarter of 2026, along with recent corporate highlights. The details of the financial performance and any significant developments were not disclosed in the article. Further information may be available in subsequent releases.

Read more →
PEPG
Mar 30, 2026
PEPGPhases
▼ -6.4%on this news· ran to -62% by day 3shared move

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

PepGen has announced topline results from the lowest dose cohort in the ongoing Phase 2 FREEDOM2 study. The results indicate favorable safety and splicing data, though specific details are not provided in the article. The study continues to progress as part of PepGen's clinical research efforts.

Read more →
PEPG
Mar 5, 2026
PEPGPhases
▼ -18.6%on this newsshared move

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

PepGen Inc. reported its financial results for Q4 and year-end 2025, highlighting the progress of its PGN-EDODM1 candidate for DM1. The company is well-funded, with sufficient cash to support operations into 2027. Promising data from the FREEDOM trial suggest PGN-EDODM1 could be a leading treatment option, with further results expected from ongoing trials in 2026.

Read more →
PEPG
Mar 5, 2026
PEPGFDA Updates
▼ -18.6%on this newsshared move

PepGen Announces Regulatory Updates on FREEDOM2

PepGen Inc. has announced regulatory updates regarding its FREEDOM2 trial, which is currently on partial clinical hold by the FDA due to concerns about preclinical studies. Despite this, the company has received clearance to initiate the trial in South Korea, Australia, and New Zealand, while dosing continues in Canada and the UK. PepGen anticipates reporting data from the trial's cohorts in 2026.

Read more →
PEPG
Mar 4, 2026
PEPGConferences/Events
▲ +5.3%on this newsshared move

March 2026 Company Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements ma

PepGen has made advancements with its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1. The company presents forward-looking statements highlighting its therapeutic potential and favorable safety profile of PGN-EDODM1. Regulatory clearances in various countries support ongoing patient enrollment, but the company warns of potential delays and uncertainties in clinical trials and regulatory interactions. The presentation emphasizes the innovative EDO platform’s ability to enhance oligonucleotide therapies.

Read more →
PEPG
Mar 3, 2026
PEPGConferences/Events

PepGen to Participate in the Leerink Global Healthcare Conference

PepGen Inc. will participate in the Leerink Global Healthcare Conference on March 10, 2026. CEO James McArthur will engage in a fireside chat, discussing the company's advancements in oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases. A webcast of the event will be available for investors.

Read more →
PEPG
Dec 9, 2025
PEPGGeneral

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

PepGen Inc. has awarded a significant inducement grant to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio. The grant includes a non-qualified stock option for 160,000 shares at an exercise price of $5.59, with a vesting schedule over four years. This award is part of PepGen's 2024 Inducement Plan and was approved by the Board of Directors.

Read more →
PEPG
Dec 8, 2025
PEPGGeneral

Julia Deutsch Lyra Strategic Advisory Jdeutsch@lyraadvisory.com

PepGen Inc. has appointed Joseph Vittiglio as Chief Business and Legal Officer, drawing from his two decades of experience in the biotechnology sector. Vittiglio's previous roles include positions at bluebird bio and Finch Therapeutics, where he led legal and business development efforts. His appointment comes as PepGen prepares for readouts from its PGN-EDODM1 program in 2026, indicating a strategic move to bolster its executive team during critical phases of development. The company focuses on advancing oligonucleotide therapies for severe neuromuscular and neurological diseases.

Read more →
PEPG
Nov 12, 2025
PEPGGeneral
▲ +10.3%on this news

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen reported strong Q3 2025 financial results, highlighting the successful outcomes from the 15 mg/kg cohort of its FREEDOM study which showed record splicing correction in DM1 patients. The company has enrolled all patients in the 5 mg/kg cohort of the FREEDOM2 study, aimed at further validating their treatment candidate PGN-EDODM1. Additionally, a recent financing round raised $115 million, securing operations through at least mid-2027. The firm plans to share data from the ongoing trials in early 2026, maintaining a focus on improving outcomes for DM1 patients.

Read more →
PEPG
Oct 1, 2025
PEPGConferences/Events

October 2025 Company Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements

PepGen's October 2025 company presentation highlights forward-looking statements regarding its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1. The company emphasizes the potential of its EDO platform in delivering oligonucleotides and the therapy's favorable safety profile, among other milestones. Challenges include risks associated with clinical trial progress and regulatory approvals, which could impact development timelines. The company is positioned well with designations for expedited review in the U.S. and EU.

Read more →
PEPG
Sep 24, 2025
PEPGPhases
▲ +36.4%on this news· ran to +202% by day 1

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

PepGen announced significant positive results from its clinical trial for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). In the Phase 1 FREEDOM-DM1 study, a mean splicing correction of 53.7% was observed after a single 15 mg/kg dose, surpassing previous reports. All patients showed improvements in splicing, and the treatment was generally well-tolerated. The company is set to report additional data from its FREEDOM2 trial in early 2026.

Read more →
PEPG
Sep 24, 2025
PEPGGeneral
▲ +36.4%on this news· ran to +202% by day 1

PepGen Announces Proposed Public Offering

PepGen Inc. has announced a proposed public offering of its common stock and pre-funded warrants, aimed at raising funds for its ongoing research and clinical development efforts. This offering is being managed by Leerink Partners and Stifel, who will also have a 30-day option to purchase additional shares. The actual size and conditions of the offering remain uncertain and dependent on market factors. PepGen's EDO platform continues to innovate in the treatment of neuromuscular and neurological diseases.

Read more →
PEPG
Aug 7, 2025
PEPGPhases
▼ -13.1%on this news

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen Inc. has reported its second-quarter financial results for 2025, highlighting progress in its lead program PGN-EDODM1 for the treatment of myotonic dystrophy type 1. The company has completed dosing in the 15 mg/kg cohort of the FREEDOM trial and is set to report topline results in early Q4 2025. Additionally, they are transitioning to the Phase 2 FREEDOM2 trial, which aims to further investigate the efficacy of multiple ascending doses of the drug. Despite a significant net loss reported this quarter, PepGen expresses confidence in its cash resources extending into mid-2026, supporting its ongoing development efforts.

Read more →
PEPG
May 28, 2025
PEPGPhases
▲ +7.5%on this news

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

PepGen Inc. announced it will discontinue development of its PGN-EDO51 program for Duchenne muscular dystrophy (DMD) after it failed to meet target dystrophin levels in the CONNECT1-EDO51 trial. The company will shift its focus to its myotonic dystrophy type 1 (DM1) program, which is in Phase 2 clinical trials. The PGN-EDO51 program did show a favorable safety profile, as all treatment-related adverse events were mild. PepGen continues to pursue its DM1 program, expecting significant results from its ongoing trials.

Read more →
PEPG
May 8, 2025
PEPGPhases
▲ +22.2%on this news

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen Inc. reported its financial results for Q1 2025, revealing promising initial data for its DM1 treatment PGN-EDODM1 showing a mean splicing correction of 29.1%. The company has upcoming data expected from both the FREEDOM-DM1 and CONNECT1-EDO51 studies in the second half of 2025 and early 2026. Additionally, PepGen is focusing on extending its cash runway and has strengthened its leadership with new Board members. Despite a rising net loss compared to the previous year, the company remains optimistic about its clinical programs.

Read more →
PEPG
Mar 31, 2025
PEPGGeneral
▼ -5.1%on this news· ran to -15% by day 3

PepGen Announces Appointment of Two New Directors to its Board

PepGen Inc. has announced the appointment of two new directors, Lisa Wyman and Dr. Mitchell H. Finer, to its Board of Directors. Both bring extensive experience in the life sciences sector, with proven track records in clinical operations and scientific innovation. Their appointments are seen as a vital addition to the company's leadership as it advances mid-stage clinical trials and aims to leverage its Enhanced Delivery Oligonucleotide platform. PepGen focuses on developing novel therapies for severe neuromuscular and neurological diseases.

Read more →

About PepGen Inc.

Boston, MA 57 employees pepgen.com
Headquarters1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next PEPG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime